What Happened?
Cambridge, MA-based Erytech Resigned Stewart Craig as Chief Technology Officer
Date of management change: July 11, 2022
Cambridge, MA-based Erytech Resigned Stewart Craig as Chief Technology Officer
Erytech is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, Erytech is developing a pipeline of product candidates for patients with high unmet medical needs. Erytech`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. Erytech is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.
Stewart Craig is Chief Technology Officer at jCyte. Previously, Stewart held various senior IT leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Morris Mike, Porter James, Williams Sandra, Sutantyo Danny, Stevens Jeremy, Sprague Darrin, Cortazzo Marina, Simms Adam, Geiger Terry, Leary Mark, Van der Aa Johannes
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.